Genomic Biomarkers Predicting Response to Selective CDK4/6 Inhibition: Progress in an Elusive Search

In this issue of Cancer Cell, Gong et al. have analyzed the sensitivity of 560 cell lines to the selective CDK4/6 inhibitor abemaciclib and have defined cancers with specific genomic “D-cyclin activating features (DCAF)” as particularly vulnerable. These findings will facilitate patient selection as development of this drug class continues. In this issue of Cancer Cell, Gong et al. have analyzed the sensitivity of 560 cell lines to the selective CDK4/6 inhibitor abemaciclib and have defined cancers with specific genomic “D-cyclin activating features (DCAF)” as particularly vulnerable. These findings will facilitate patient selection as development of this drug class continues.